8-K current report · filed Sep 29, 2026

Aldeyra Therapeutics, Inc. (ALDX) 8-K Current Report: September 29, 2026

Item 7.01Item EX-99.1Item EX-99.2Item 8.01ALDX overview

Short answer

Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on September 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 8.01 (Other Events). Aldeyra plans to appeal FDA’s March 16, 2026 rejection of reproxalap’s dry-eye NDA through a Formal Dispute Resolution Request.

Aldeyra Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • Aldeyra plans to appeal FDA’s March 16, 2026 rejection of reproxalap’s dry-eye NDA through a Formal Dispute Resolution Request
  • FDRR submission and FDA Office of New Drugs meeting expected in Q4 2026, creating a potential approval-pathway catalyst
  • Reproxalap remains commercially unapproved, preserving regulatory and execution risk despite the appeal
  • Operational cash runway extended into 2029, reducing near-term financing pressure during the regulatory process

Item 8.01 · Other Events

  • Aldeyra plans an FDA dispute resolution request challenging the March 16, 2026 rejection of reproxalap for dry eye disease
  • Reproxalap approval remains uncertain, creating a regulatory catalyst and significant binary risk for investors
  • Projected operational cash runway extended into 2029, reducing near-term financing pressure
  • Outcome depends on FDA discussions, FDRR timing and potential NDA resubmission acceptance

Item EX-99.1 · Exhibit EX-99.1

  • Aldeyra plans a Formal Dispute Resolution Request to FDA’s Office of New Drugs after three complete response letters for reproxalap
  • OND meeting expected in Q4 2026, but FDRR timing and outcome remain uncertain
  • Nine efficacy trials supported the NDA; five achieved all primary endpoints and 9 of 14 endpoints had P<0.05
  • FDA’s latest letter cited insufficient totality of evidence without requesting another clinical trial, preserving a potential regulatory path
  • $45.1M cash as of June 30, 2026, with company-estimated runway into 2029 supporting FDRR and ADX-2191 development

Item EX-99.2 · Exhibit EX-99.2

  • Aldeyra plans an FDA Formal Dispute Resolution Request in Q4 2026 to appeal reproxalap’s March 16, 2026 rejection for dry eye disease
  • Regulatory risk remains high: three Complete Response Letters, with the latest citing insufficient totality of evidence rather than requesting another trial
  • Reproxalap has nine controlled trials, including five achieving all multiplicity-controlled primary endpoints, supporting Aldeyra’s appeal case
  • Cash and equivalents of $45.1M as of June 30, 2026, now support an operational runway extending into 2029
  • FDA Office of New Drugs review timing remains uncertain, potentially involving additional information, experts, or an advisory panel

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aldeyra Therapeutics, Inc. 8-K filings

Get the next ALDX 8-K as it lands

Follow ALDX for push alerts, or ask the research agent what this filing means.